The restructuring is the third cost-cutting action in FY2026, with the Multiomics segment bearing the brunt. Monitor the Q1 FY2027 10-Q for actual charge amounts and whether the $11M savings target is on track. The $7M cash burn from restructuring is manageable but adds to any existing cash flow pressure.
Price Chart
Executive Summary
Azenta announced a restructuring plan within its Multiomics segment, involving workforce reductions and closure of three North American lab sites. The company expects pre-tax charges of $11M-$13M (including a $9M impairment) and ~$7M in cash expenditures, targeting $11M in annualized cost savings by March 2027. This follows two smaller, immaterial restructurings earlier in FY2026, signaling ongoing operational pressure.
Key Facts
- Restructuring plan approved Oct 5, 2026 within Multiomics segment
- Closure of three North American laboratory sites and workforce reductions
- Estimated aggregate pre-tax charges of $11.0M to $13.0M
- Approximately $9.0M in asset impairment charges (Item 2.06)
- Approximately $3.0M in employee severance and other restructuring charges
- Estimated future cash expenditures of approximately $7.0M
- Charges expected in fiscal year ending September 30, 2027
- Plan expected to be substantially complete by March 31, 2027
- Expected annualized cost savings of approximately $11.0M once fully implemented
- Separate from two earlier immaterial restructurings in FY2026 (Aug in Sample Management Solutions, Sept in Multiomics)
Financial Impact
Pre-tax charges of $11M-$13M, with $7M cash outflow; $11M annualized cost savings targeted
Risk Factors
- Execution risk: failure to achieve $11M in annualized savings or delays in completing actions by March 2027
- Customer disruption from lab closures could pressure Multiomics revenue
- Additional restructuring actions may be identified, increasing total charges
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-065292 |
| Document: 0001628280-26-065292-index-headers.html | 0001628280-26-065292 |
| Document: 0001628280-26-065292-index.html | 0001628280-26-065292 |
| Document: 0001628280-26-065292.txt | 0001628280-26-065292 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $35.89 $37.18 | ▼ −3.59% | ▼ −4.57% | $39.08 (−8.89%) |
Sep 17, 2026 5w ago | 8-K | $33.63 $34.20 | ▲ +1.69% | ▲ +1.09% | $39.08 (+16.21%) |
Sep 4, 2026 7w ago | 8-K | $31.33 $32.04 | ▲ +2.27% | ▲ +3.48% | $39.08 (+24.74%) |
Aug 24, 2026 9w ago | 8-K | $32.88 $32.65 | ▼ −0.70% | ▼ −1.17% | $39.08 (+18.86%) |
Aug 8, 2026 11w ago | Institutional Cluster | $33.33 $33.58 | ▲ +0.75% | ▲ +0.80% | $39.08 (+17.25%) |
Aug 4, 2026 12w ago | Press Release | $31.82 $33.53 | ▲ +5.37% | ▲ +5.02% | $39.08 (+22.82%) |
Jul 8, 2026 15w ago | 8-K | $24.51 $25.44 | ▲ +3.79% | ▲ +2.93% | $39.08 (+59.45%) |
May 5, 2026 25w ago | 8-K | $18.38 $17.53 | ▲ +4.62% | ▲ +5.76% | $39.08 (−112.62%) |
Apr 7, 2026 29w ago | 8-K | $21.71 $24.26 | ▲ +11.75% | ▲ +6.42% | $39.08 (+80.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers